High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: The Efa VIP study (Efavirenz in very immunosuppressed patients)

1. Arribas, J.R.
2. Pulido, F.
3. Miró, J.M.
4. Costa, M.A.
5. González, J.
6. Rubio, R.
7. Peña, J.M.
8. Torralba, M.
9. Lonca, M.
10. Lorenzo, A.
11. Del Palacio, A.
12. Vázquez, J.J.
13. Gatell, J.M.